Neuroscience
MARS alleviates neurological progression in liver disease-related coma
Published in Hepatitis Weekly, October 27th, 2003
"In our 3-year experience, we treated 63 patients with molecular adsorbent recirculating system (MARS). The patients were divided as follows: 10 primary non-function (PNF) 16%, 10 delayed non-function (DNF) 16%, 16 fulminant hepatitis (FH) 24%, 23 acute decompensation of chronic liver disease (ACLF) 38%, and 4 hepatic resection 6%. All patients who underwent MARS treatment had bilirubin >15 mg/dL, Glasgow Coma Score between 9 and 11, ammonium >160 mcg/dL and non-coagulability," according to researchers in Italy.
"The determining factors taken into consideration for the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-10-27)
More Articles from Hepatitis Weekly
- Transplantation
Interferon therapy prior to liver transplant curbs hepatitis C recurrence - Diet and Nutrition
Creatine supplementation causes liver inflammation in mice but not rats - Liver Cirrhosis
Suppression subtractive hybridization characterizes the genetics of cirrhosis - Virology
The 5' untranslated region of GB virus C highlights genotypic differences - AIDS Research
U.S.-Russian initiative to intensify cooperation in fight against disease - Adverse Drug Effects
Apoptosis precedes necrosis in acetaminophen-induced liver injury - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
